Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma.

Abstract

In a multicenter, phase II trial, CI-958, a benzothiopyranoindazole DNA intercalator, was administered to 18 patients who had not received prior chemotherapy for metastatic colorectal cancer. The drug was given by intravenous infusion at a dose of 700 mg/m2 every 21 days. There were no objective responses. Grades III and IV toxic effects were limited to granulocytopenia in 42% of courses and anemia in 5% of courses. There was one case of grade III increase in transaminases. Our results show that at this dose and schedule, CI-958 lacks activity against colorectal cancer.

• Authors: P M Hoff, J A Ellerton, S R Dakhil, R J Winn, J L Abbruzzese, R Pazdur
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 23 Issue 6 Pg. 602-4 (Dec 2000) ISSN: 0277-3732 [Print] United States
• PMID: 11202806 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Indazoles
• ledoxantrone

Topics

• Adenocarcinoma (drug therapy, secondary)
• Adult
• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Colorectal Neoplasms (drug therapy, pathology)
• Female
• Humans
• Indazoles (administration & dosage, therapeutic use)
• Infusions, Intravenous
• Male
• Middle Aged